Lazertinib Alternatives: How It Compares to Other EGFR Inhibitors

Lazertinib vs Osimertinib (Tagrisso)

The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT04487080) enrolling 1,074 participants, primary completion 2023-08.

Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR): Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months; Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months; Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months

Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.

Lazertinib vs Erlotinib (Tarceva)

No head-to-head Phase-3 trial directly compares Lazertinib with Erlotinib.

In separate pivotal trials, Lazertinib reported 23.7months PFS at median (NCT04487080) versus 6.7months OS at median for Erlotinib (NCT00036647).

Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.

Lazertinib vs Gefitinib (Iressa)

The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT04248829) enrolling 393 participants, primary completion 2022-07.

Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment: Gefitnib 250 mg 9.7 Months; Lazertinib 240 mg 20.6 Months

Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.

Several investigational agents are in active Phase 3 development. These include Afatinib from Boehringer Ingelheim, with its lead Phase 3 trial NCT01523587. This agent is an earlier-generation EGFR TKI compared to Lazertinib. Aumolertinib, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd., is also undergoing Phase 3 evaluation, with a key study NCT04923906. Aumolertinib shares a similar third-generation EGFR TKI mechanism with Lazertinib. Additionally, Icotinib from Betta Pharmaceuticals Co., Ltd. is in Phase 3 development, as exemplified by NCT01040780, representing another earlier-generation EGFR TKI.

Lazertinib is an EGFR tyrosine kinase inhibitor, a class of targeted therapies designed to inhibit tumor growth in specific patient populations. While specific comparative efficacy and safety data for Lazertinib are not detailed here, newer agents in this class are often developed with the aim of offering potential advantages such as improved efficacy, a more favorable safety profile, or convenient once-daily dosing. Clinicians considering Lazertinib would typically evaluate its profile based on available clinical trial data for specific patient characteristics and tumor mutations.

In contrast, other EGFR inhibitors offer established profiles. Osimertinib (Tagrisso) has demonstrated a median progression-free survival of 18.9 months and is dosed 80 mg orally once daily. Erlotinib (Tarceva) has a median overall survival of 6.7 months and is available for non-small cell lung cancer (150 mg orally once daily) and pancreatic cancer (100 mg orally once daily), offering a broader indication. Gefitinib (Iressa) has shown an overall response rate of 69.8% with a 250 mg orally once daily dose. These agents, with their longer track records and specific efficacy metrics, may be preferred based on factors such as established safety profiles, cost considerations, or specific indications like Erlotinib's use in pancreatic cancer.

Ultimately, the choice of EGFR inhibitor is a complex clinical decision that should be made by the prescriber in consultation with the patient, considering individual patient factors, tumor characteristics, and the full body of available evidence.